Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...4546474849505152535455...143144»
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion date, Trial primary completion date, Metastases:  Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) -  Dec 17, 2021   
    P2,  N=5, Active, not recruiting, 
    Considering the limitations in this study, more well-designed RCTs are needed in the future to validate the results. Trial completion date: Mar 2022 --> Jun 2024 | Trial primary completion date: Aug 2020 --> Jun 2023
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  NK Cell-Dependent Antibody-Mediated Immunotherapy Is Improved In Vitro and In Vivo When Combined with Agonists for Toll-like Receptor 2 in Head and Neck Cancer Models. (Pubmed Central) -  Dec 17, 2021   
    The immunosuppressive character of head and neck cancers may explain the relatively low response rates to antibody therapy targeting a tumor antigen, such as cetuximab, and anti-PD-1 checkpoint inhibition...In conclusion, combining tumor-targeting antibody-based immunotherapy with TLR stimulation represents a promising treatment strategy to improve the clinical outcomes of cancer patients. This treatment could well be applied together with other therapeutic strategies such as anti-PD-(L)1 checkpoint inhibition to further overcome immunosuppression.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Acute statin treatment improves antibody accumulation in EGFR- and PSMA-expressing tumors. (Pubmed Central) -  Dec 16, 2021   
    These data show the potential of statins as pharmacologic modulators of endocytic proteins for improved tumors' accumulation of monoclonal antibodies. The translational significance of these findings lies in the potential of statins to temporarily modulate the heterogeneous presence of receptors at the cell membrane, a characteristic often associated with poor response in tumors to therapeutic antibodies.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Prolonged cetuximab treatment promotes p27-mediated G1 arrest and autophagy in head and neck squamous cell carcinoma. (Pubmed Central) -  Dec 16, 2021   
    Results of the present study elucidate the cetuximab-dependent inhibition of cell migration, resulting in high cell density-related stress and persistent cell-cycle arrest at G1 phase culminating in autophagy. These findings provide novel molecular insights related to the anti-tumor effects of prolonged cetuximab treatment with the potential to improve future therapeutic strategy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope. (Pubmed Central) -  Dec 16, 2021   
    Single particle analysis of the sEGFR-528 Fab complex via electron microscopy clearly showed the binding of 528 to domain III of sEGFR, the domain to which EGF and cetuximab bind, explaining its antagonistic activity. Comparison between the two-dimensional class average and the cetuximab/sEGFR crystal structure revealed that 528 binds to a site that is shifted from, rather than identical to, the cetuximab epitope, and may exclude known drug-resistant EGFR mutations.
  • ||||||||||  Clinical, Review, Journal:  Targeted agents in older patients with gastrointestinal cancers - An overview. (Pubmed Central) -  Dec 16, 2021   
    However, even if most decisions regarding the use of targeted agents in older patients with gastrointestinal cancer remain guided by subanalyses of large trials, data from recent older adult-specific trials are beginning to emerge, particularly in colorectal cancer. This review aims to summarize the existing evidence on treatment of older patients with gastrointestinal carcinomas (colon and rectum, stomach, esophagus, liver, and pancreas) with targeted agents (cetuximab, panitumumab, bevacizumab, ramucirumab, aflibercept, regorafenib, encorafenib, trastuzumab, sorafenib, lenvatinib, cabozantinib, erlotinib, olaparib), and place the evidence in a geriatric oncology perspective.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Efficacy of transcatheter arterial chemoembolization combined with capecitabine and cetuximab in the treatment of colorectal cancer with liver metastasis. (Pubmed Central) -  Dec 16, 2021   
    This review aims to summarize the existing evidence on treatment of older patients with gastrointestinal carcinomas (colon and rectum, stomach, esophagus, liver, and pancreas) with targeted agents (cetuximab, panitumumab, bevacizumab, ramucirumab, aflibercept, regorafenib, encorafenib, trastuzumab, sorafenib, lenvatinib, cabozantinib, erlotinib, olaparib), and place the evidence in a geriatric oncology perspective. The short-term efficacy of TACE combined with capecitabine and cetuximab in treating colorectal cancer with liver metastasis is superior to that of TACE combined with cetuximab.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  EGFR-RAS-MAPK signaling is confined to the plasma membrane and associated endorecycling protrusions. (Pubmed Central) -  Dec 16, 2021   
    Endogenous mCherry-tagged RAF1, an effector of RAS, was recruited to the plasma membrane, with subsequent accumulation in mNG-NRAS-containing TERCs. We propose that a small pool of surface EGFRs sustain signaling within the RAS-ERK1/2 pathway and that RAS activation persists in TERCs, whereas endosomal EGFR does not significantly contribute to ERK1/2 activity.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Journal, HEOR:  Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer. (Pubmed Central) -  Dec 16, 2021   
    Differences in costs between the two arms (encorafenib plus cetuximab vs FOLFIRI plus cetuximab) was 59 501 €, with a cost of 17 500 € per month of overall survival-gain. Combining pharmacological costs of drugs with the measure of efficacy represented by overall survival, at the actual prize encorafenib cannot be considered cost-effectiveness for second-line treatment of BRAFV600-mutated metastatic colorectal cancer.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Journal:  Mutation analysis of a 10-gene panel for colorectal cancer in Huizhou, Guangdong Province of China. (Pubmed Central) -  Dec 16, 2021   
    Combining pharmacological costs of drugs with the measure of efficacy represented by overall survival, at the actual prize encorafenib cannot be considered cost-effectiveness for second-line treatment of BRAFV600-mutated metastatic colorectal cancer. Gene mutations detected by a 10-gene panel were useful for targeting therapy of CRC in Huizhou.
  • ||||||||||  MK-1084 / Merck (MSD), Otsuka
    Enrollment open, Combination therapy, Monotherapy, Metastases:  A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) (clinicaltrials.gov) -  Dec 14, 2021   
    P1,  N=185, Recruiting, 
    Gene mutations detected by a 10-gene panel were useful for targeting therapy of CRC in Huizhou. Not yet recruiting --> Recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Preclinical, Journal:  Modeling of Personalized Treatments in Colon Cancer Based on Preclinical Genomic and Drug Sensitivity Data. (Pubmed Central) -  Dec 13, 2021   
    Background for this experimental preclinical study was that, by analyzing the tumor growth inhibition in the PDX models by cetuximab treatment, a broad heterogenic response from complete regression to tumor growth stimulation was observed. To provide confirmation of the hypothesis that drug combinations blocking alternatively activated oncogenic pathways may improve therapy outcomes, 25 models out of the well-characterized ONCOTRACK PDX panel were subjected to treatment with a drug combination scheme using four approved, targeted cancer drugs.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Surface Engineering of Escherichia coli-Derived OMVs as Promising Nano-Carriers to Target EGFR-Overexpressing Breast Cancer Cells. (Pubmed Central) -  Dec 7, 2021   
    Interestingly, despite a lower binding affinity of the engineered OMVs relative to the positive control Cetuximab, it was strong enough to identify these cells...Regarding the EGFR-binding affinity of the engineered OMVs and their cellular uptake, they are presented here as a potential carrier for cell-specific drug delivery to treat a wide variety of cancer cells. Interestingly, the engineered OMVs are capable of reaching the cytoplasm while escaping the endosome due to the incorporation of a fusogenic GALA peptide in the construct.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. (Available On Demand) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_635;    
    P1/2
    The E+C+N regimen met its predefined efficacy endpoint and suggests a role for immunotherapy as a novel combination approach for this specific subpopulation of MSS metastatic CRC. A follow-up randomized phase II trial (SWOG 2107) to evaluate encorafenib/cetuximab with or without nivolumab in pts with MSS, BRAFV600E metastatic CRC will activate in early 2022.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, VS-6766 / Verastem
    A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC). (In-Person Only | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_610;    
    Regorafenib or TAS-102 is commonly used however, the modest clinical benefit, and toxicity limit their use...Adagrasib (a KRAS G12C inhibitor) was used with/without cetuximab in heavily pretreated CRC pts harboring KRAS G12C mts...Phase 1b CodeBreaK101 study evaluating sotorasib (KRAS G12C inhibitor) and panitumumab (anti-EGFR) combination in KRAS G12C mt CRC showed 15.4% confirmed ORR and 26.9% unconfirmed ORR...Eligible pts include those with metastatic CRC and progression after 5-FU, oxaliplatin, irinotecan and VEGFi therapy...The study is funded by research grants from Verastem Oncology. Cetuximab will be supplied by Eli Lilly.
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Gene expression-based personalized prescription of targeted drugs in colorectal cancer. (In-Person & On Demand | Level 1, West Hall; Online Only) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_541;    
    Our results suggest that RNA profiling in tumor samples may be helpful for personalizing prescriptions of targeted therapeutics in CRC. Using recent biopsies is essential to obtain robust estimates of targeted drugs efficacy.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
    Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models. (In-Person & On Demand | Level 1, West Hall; Poster Board - K9) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_535;    
    Taken together, results from our study suggest that the addition of chemotherapy to BRAF+EGFR targeted therapy can further increase the magnitude of response in BRAFV600E mCRC and is a promising combination now being explored clinically. Additionally, this research will substantially contribute to our understanding of the genetic and molecular bases of resistance to target therapies and chemo-based approach in BRAFV600Econtext.